Welcome to the e-CCO Library Archive!

Filter:

P374. The occurrence of Escherichia coli pathotypes and their relation to the disease activity in patients with Crohn's disease and ulcerative colitis

P374

The clinical usefulness of the web based message system between patients with Crohn’s disease and their physicians

Authors:

B.I. Jang¹, K.O. Kim*¹, E.S. Kim², K.S. Park², K.B. Cho², E.Y. Kim³, J.T. Jung³, S.W. Jeon⁴, H.S. Lee⁴, C.H. Yang⁵, Y.K. Lee⁵

¹Yeungnam University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Daegu, Korea, Republic of, ²Keimyung University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Daegu, Korea, Republic of, ³Catholic University of Daegu School of Medicine, Internal Medicine, Daegu, Korea, Republic of, ⁴Kyungpook National University Hospital, Gastroenterology, Daegu, Korea, Republic of, ⁵Dongguk University College of Medicine, Division of gastroenterology and Hepatology, department of Internal Medicine, Kyungju, Korea, Republic of

P375.

Primary response to infliximab therapy in IBD patients is reflected in the normalisation of the haemostatic profile

Authors:

L. Bollen¹, N. Vande Casteele¹, M. Peeters¹, P. Declerck¹, M. Ferrante², S. Vermeire², A. Gils¹, ¹KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Therapeutic and Diagnostic Antibodies, Leuven, Belgium, ²KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Center for GastroIntestinal Disorders (TARGID), Leuven, Belgium

P375. Efficacy, safety, impact on natural history of long-term treatment with thiopurines in Crohn's disease patients. A single center experience

P375. Microbiota in Crohn's perianal fistulae

P375. Sarcopaenia in inflammatory bowel disease (IBD), a prominent finding in males with normal BMI: What are we missing?

Authors:

R. Bryant¹, C. Schultz², R. Grafton¹, J. Hughes¹, C. Goess¹, M. Schoeman¹, D. Bartholomeusz¹, J. Andrews¹, ¹Royal Adelaide Hospital, Department of Gastroenterology and Hepatology, Adelaide, Australia, ²Royal Adelaide Hospital, Department of Nuclear Medicine, Adelaide, Australia

P375

Efficacy of Exclusive Enteral Nutrition (EEN) in Active Crohn’s Disease with Complications or Failure of Medical Treatment

Authors:

Q. Yang*¹, X. Gao¹, M. Zhi¹, H. Chen¹, N. Ding¹, S. Hu², J. Guo¹, P. Hu¹

¹The Sixth Affiliated Hospital of Sun Yat-sen University(Guangdong Gastrointestinal Hospital), Department of Gastroenterology, Guangzhou, China, ²The Sixth Affiliated Hospital of Sun Yat-sen University (Guangdong Gastrointestinal Hospital), Department of Gastroenterology, Guangzhou, China

P376.

Prevalence of surgical treatment of Crohn's disease according to period of diagnosis: preliminary data of a 30-year experience in a single centre

Authors:

G. Pellino¹, M. Patturelli², A. Cirillo², L.A. Vastarella², R. D'Urso², P. Esposito², M.I. Russo², F. Selvaggi¹, G. Riegler², ¹Second University of Naples, Unit of General Surgery, Naples, Italy, ²Second University of Naples, Gastroenterology Unit, Department of Clinical and Experimental Medicine, Naples, Italy

P376. Effect of intravenous iron administration on thrombocytosis in inflammatory bowel disease

P376. Phylogenetic and phenotypic characterisation of Faecalibacterium prausnitzii isolates from the human large intestine

P376. Safety results comparison of the pediatric ADAPT trial cohort to a seven years retrospective in 656 adult UC patients

Authors:

T. Ruuska¹, R. Gruber², ¹Tampere University Hospital, Dept. of Pediatrics, Tampere, Finland, ²Otsuka Pharmaceutical Europe Ltd., Frankfurt, Germany

P376

Mucosal healing in IBD: Therapy maintenance or de-escalation therapeutic approach in patients achieving mucosal healing

Authors:

G. Costantino*¹, L. Amato¹, A. Sitibondo¹, A. Alibrandi², W. Fries¹

¹University, Dept. of Clinical and Experimental Medicine, Messina, Italy, ²University, Dept. of Economical, Financial, Social, Environmental, Statistical and Territorial Sciences, Messina, Italy

P377.

Pregnancy outcome and counselling of anti-TNF-alpha treated IBD women: an ongoing international multicentre study

Authors:

M. Julsgaard¹, L.A. Christensen¹, I. Lawrence², R. Gearry³, W. Connell⁴, A. Grosen¹, L. Svenningsen⁵, J.M. Andrews⁶, P. Bampton⁷, A. Walsh⁸, G.T. Moore⁹, G. Radford-Smith¹⁰, S. Brown⁴, C.L. Hvas¹, J. Kjeldsen¹¹, S.J. Connor¹², M.P. Sparrow¹³, J. Fallingborg¹⁴, S.J. Bell⁴, ¹Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark, ²Fremantle Hospital, Centre for Inflammatory Bowel Disease, Fremantle, Australia, ³University of Otago, Christchurch hospital, Dept. of Medicine (Gastroenterology), Christchurch, New Zealand, ⁴St Vincent's Hospital & University of Melbourne, Gastroenterology, Melbourne, Australia, ⁵Herning Hospital, Dept. of Medicine (Gastroenterology), Herning, Denmark, ⁶Royal Adelaide Hospital, University of Adelaide, IBD Service, Dept of Gastroenterology & Hepatology & School of Medicine, Adelaide, Australia, ⁷Flinders Medical Centre, Gastroenterology and Hepatology, Adelaide, Australia, ⁸St Vincent's Hospital, Dept. of Gastroenterology, Sydney, Australia, ⁹Monash University, Monash Health, Dept. of Gastroenterology, Melbourne, Australia, ¹⁰Royal Brisbane and Women's Hospital, Gastroenterology, Brisbane, Queensland, Australia, ¹¹Odense University Hospital, Dept. of Gastroenterology and Hepatology, Odense, Denmark, ¹²Liverpool Hospital & University of NSW, Dept. of Gastroenterology, Sydney, Australia, ¹³Alfred Hospital and Monash University, Dept. of Gastroenterology, Melbourne, Australia, ¹⁴Aalborg Hospital, Department of Gastroenterology, Aalborg, Denmark

P377. Effect of oligofructose enriched inulin (OF-IN) on bacterial composition and disease activity of Crohn's disease patients: Results from a double-blind randomized controlled trial

P377. Long-term outcome after infliximab treatment for distal refractory ulcerative colitis. A single tertiary center experience

P377. Safety profile and discontinuation rate of infliximab and adalimumab in patients with Crohn's disease and ulcerative colitis: experience from a tertiary care hospital in Qatar over a 7 year period

Authors:

M. Sharma¹, S. Al Kaabi¹, N. Al Dweik¹, A. John¹, H. Wani¹, K. Al Ejji¹, M. Al Mohanadi¹, M. Derbala¹, R. Yacoub¹, F. Pasic¹, T. Butt¹, M. ElBedawi², R. Singh³, ¹Hamad Medical Corporation, Medicine, Doha, Qatar, ²Weill Cornell Medical School in Qatar, Medicine, Doha, Qatar, ³Hamad Medical Corporation, CCS, Doha, Qatar

P377

Assessment of safety and efficacy of ferric carboxymaltose (Ferinject ®) in the management of iron deficiency with anaemia (IDA) or without anaemia in children and adolescents with inflammatory bowel disease (IBD)

Authors:

S. Hachemi*¹, M. Mutalib¹, S. Chadokufa¹, B. Huggett¹, S. Sider¹, N. Shah¹, L. Whitley², S. McCartney², F. Kiparissi^{1, 2}

¹Great Ormond Street Hospital, Paediatric Gastroenterology, London, United Kingdom, ²University College London Hospitals NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom

P378.

Predictors of sub-therapeutic infliximab or adalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions

Authors:

R. Goldberg¹, L. Beswick², D. Van Langenberg³, B. Sally⁴, O. Rosella², P. Gibson², G. Moore¹, ¹Monash University, Monash Health, Dept. of Gastroenterology, Melbourne, Australia, ²Alfred Health, Department of Gastroenterology, Melbourne, Australia, ³Eastern Health, Department of Gastroenterology, Melbourne, Australia, ⁴St Vincent's Hospital & University of Melbourne, Gastroenterology, Melbourne, Australia

P378. Bacterial colonisation of the colonic mucous gel layer: Comparative analysis of mucosal biopsies and adjacent mucous

P378. High restarting rate among patients with Crohn's disease after cessation of one-year treatment period with biologicals: Result of national RASH study


All Abstracts Documents Images Podcasts Webcasts
search by: